|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:semaglutide
|
|
gptkbp:approvalYear
|
2021-06-04
|
|
gptkbp:associatedWith
|
gptkb:Ozempic
gptkb:Rybelsus
|
|
gptkbp:ATCCode
|
gptkb:A10BJ06
|
|
gptkbp:brand
|
gptkb:semaglutide
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
personal or family history of medullary thyroid carcinoma
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
about 1 week
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Wegovy
|
|
gptkbp:indication
|
obesity
weight management
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Novo_Nordisk
|
|
gptkbp:mechanismOfAction
|
GLP-1 receptor agonist
|
|
gptkbp:pregnancyCategory
|
not recommended in pregnancy
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
constipation
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:targetAudience
|
adults with BMI ≥27 kg/m² with at least one weight-related condition
adults with BMI ≥30 kg/m²
|
|
gptkbp:weightLossEffect
|
clinically significant
|
|
gptkbp:bfsParent
|
gptkb:Novo_Nordisk
gptkb:Mounjaro
|
|
gptkbp:bfsLayer
|
6
|